Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 7:43 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Type 2 Diabetes, Diabetic Kidney Disease
Interventions: SGLT2 inhibitor; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diabetic Foot Ulcer
Interventions: 0.03% DSC127 topical gel; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 261 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 21
States / cities: Mobile, Alabama • Chino, California • Fresno, California + 16 more

Conditions: Type 2 Diabetes, Overweight and Obese Adults
Interventions: Low-fat, vegan diet; Behavioral
Lead sponsor: Physicians Committee for Responsible Medicine; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Type 2 Diabetes
Interventions: Not listed
Lead sponsor: Wayne State University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Metastatic Prostate Cancer, Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Cancer
Interventions: Evofosfamide, Zalifrelimab, Balstilimab; Drug
Lead sponsor: ImmunoGenesis; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infertility
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: Saxagliptin, Metformin XR, Placebo matching Metformin XR, Placebo matching Saxagliptin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 12
States / cities: Phoenix, Arizona • Redlands, California • Tustin, California + 9 more

Conditions: Growth Hormone Deficiency
Interventions: Growth hormone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Advanced Solid Malignancies, Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions: BMS-986523, Gemcitabine, Nab-Paclitaxel, Cetuximab, Pembrolizumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 4
States / cities: Baltimore, Maryland • San Antonio, Texas • West Valley City, Utah + 1 more

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Interventions: Relacorilant, 100 mg and 25 mg, Nab-paclitaxel; Drug
Lead sponsor: Corcept Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 18
States / cities: Scottsdale, Arizona • Duarte, California • Los Angeles, California + 14 more

Conditions: Ovary Cancer, Endometrial Cancer, Uterine Cancer
Interventions: FAST Intervention; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions: Acupressure Therapy, Best Practice, Biospecimen Collection, Questionnaire Administration; Procedure · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 65 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Diabetes Mellitus, Type 2
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Mild Autonomous Cortisol Secretion (MACS)
Interventions: Osilodrostat (Isturisa); Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 1 Diabetes
Interventions: High-Resistance Inspiratory Muscle Strength Training, Sham Inspiratory Muscle Strength Training; Device
Lead sponsor: Florida State University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 2
States / cities: Tallahassee, Florida

Conditions: Breast Cancer, Lung Cancer, Ovarian Cancer
Interventions: HER-2/neu peptide vaccine, sargramostim; Biological
Lead sponsor: University of Washington; Other
Eligibility: Up to 120 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer
Interventions: CLSP-5282; Drug
Lead sponsor: Clasp Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 140 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Durham, North Carolina • Philadelphia, Pennsylvania • Nashville, Tennessee + 1 more

Conditions: Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), Female, Adult, Endothelial Function (Reactive Hyperemia), Arterial Stiffness, Cognition, Oxidative Stress, Gut Microbiota, Overweight, Inflammation, Microvascular Function, Body Composition
Interventions: Wild Blueberry, Placebo; Dietary Supplement
Lead sponsor: Georgia State University; Other
Eligibility: 20 Years to 65 Years · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Pituitary Tumor, Meningioma, Rathke Cleft Cysts, Chordoma, Chondrosarcoma, Craniopharyngioma, Encephalocele, Esthesioneuroblastoma
Interventions: Not listed
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Timeline: 2019 – 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Diabetes
Interventions: Automated telephone health status assessments with nurse follow-up.; Procedure
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years to 75 Years
Enrollment: 272 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1999
U.S. locations: 1
States / cities: Palo Alto, Michigan

Conditions: Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma, Stage III Adrenal Cortical Carcinoma AJCC v8, Stage IV Adrenal Cortical Carcinoma AJCC v8, Unresectable Adrenal Cortical Carcinoma
Interventions: Biospecimen Collection, Cabozantinib, Cemiplimab, Computed Tomography, Magnetic Resonance Imaging; Procedure · Drug · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years and older
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 81
States / cities: Phoenix, Arizona • La Jolla, California • Madera, California + 60 more

Conditions: Hypoglycemia
Interventions: Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog); Procedure
Lead sponsor: Florida Atlantic University; Other
Eligibility: 20 Years to 90 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Type 2 Diabetes
Interventions: AZD1656, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 30 Years to 75 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Type 2 Diabetes Mellitus, Healthy
Interventions: PF-04991532; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 2
States / cities: Anaheim, California • DeLand, Florida

Search by objective public record fields.

Mechanism of SGLT2 Inhibition in the Kidney

Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use

Plant-Based Online Weight Loss Through Education and Resources Program and Study

Effect of Januvia on Ghrelin and Other Gut Hormones in Patients With Diabetes

A Study of Evofosfamide in Combination With Zalifrelimab and Balstilimab

Ovarian Stem Cells From Women With Ovarian Insufficiency

Study To Evaluate 24 Hour Blood Sugar Control (24-hour Mean Weighted Glucose) In Subjects That Are Taking Saxagliptin 5 mg Added Onto Metformin XR 1500 XR mg Compared To Subjects Taking Metformin XR 1500 mg Up-titrated To Metformin XR 2000 mg

Adipose Tissue and Circulating Markers of Inflammation in GH Deficiency and Changes With GH Therapy

A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies

Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer

A 6-Week Study Of PF-05175157 In Type 2 Diabetes Mellitus

Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)

Inspiratory Muscle Strength Training in Adults With Type 1 Diabetes

HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer

A Study of CLSP 5282 in HLA-A*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101)

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

Long-Term Longitudinal QoL in Patients Undergoing EEA

Automated Calls With Nurse Follow-Up to Improve Diabetes Ambulatory Care

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

Effects of Pulsatile Intravenous Insulin Delivery on Hypoglycemic Unawareness

To Evaluate Safety and Tolerability After Multiple Oral Doses of AZD1656 in Type 2 Diabetes Patients on Top of Metformin

Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics Of PF-04991532